Arax Advisory Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.28M Hold
21,304
– – 0.01% 1204
2026
Q2
$883K Hold
15,439
– – 0.01% 1290
2026
Q1
$174K Buy
3,104
+2,981
+2,424% +$174K ﹤0.01% 1150
2025
Q4
$7.31K Sell
123
-103,211
-100% -$5.62M ﹤0.01% 2646
2025
Q3
$5.6M Buy
103,334
+103,251
+124,399% +$5.9M 0.08% 205
2025
Q2
$4.56K Sell
83
-31
-27% -$1.82K ﹤0.01% 2287
2025
Q1
$8.06K Buy
114
+76
+200% +$5.11K ﹤0.01% 1625
2024
Q4
$2.5K Buy
38
+26
+217% +$1.74K ﹤0.01% 1955
2024
Q3
$844 Buy
12
+3
+33% +$251 ﹤0.01% 2308
2024
Q2
$741 Buy
+9
New +$749 ﹤0.01% 2252
2023
Q4
– Sell
-7
Closed -$620 – 1345
2023
Q3
$620 Sell
7
-11
-61% -$979 ﹤0.01% 1216
2023
Q2
$1.56K Sell
18
-1
-5% -$94 ﹤0.01% 1035
2023
Q1
$1.85K Hold
19
– – ﹤0.01% 1000
2022
Q4
$1.97K Hold
19
– – ﹤0.01% 943
2022
Q3
$2K Buy
+19
New +$1.69K ﹤0.01% 939
2022
Q1
– Sell
-15
Closed -$1K – 1154
2021
Q4
$1K Buy
+15
New +$1.24K ﹤0.01% 973
2018
Q3
– Sell
-237
Closed -$22K – 630
2018
Q2
$22K Buy
237
+2
+0.9% +$175 0.01% 288
2018
Q1
$19K Buy
+235
New +$20.2K 0.01% 283
2017
Q3
– Sell
-19
Closed -$2K – 469
2017
Q2
$2K Hold
19
– – ﹤0.01% 439
2017
Q1
$1K Hold
19
– – ﹤0.01% 480
2016
Q4
$2K Hold
19
– – ﹤0.01% 456

Other funds holding BMRN

Arax Advisory Partners's BMRN Position: Q3 2026 in Review

Arax Advisory Partners reported 21,304 shares of BioMarin Pharmaceuticals (BMRN) worth $1.28M in Q3 2026. The position accounts for 0.01% of the portfolio, ranked #1204.

Arax Advisory Partners first reported a position in BMRN in Q4 2016 and has held it in 21 quarters since. The position peaked at $5.6M in Q3 2025. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Arax Advisory Partners held 21,304 shares of BioMarin Pharmaceuticals worth $1.28M as of Q3 2026.
  • BioMarin Pharmaceuticals made up 0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #1204 holding.
  • Arax Advisory Partners first reported a position in BioMarin Pharmaceuticals in Q4 2016 and has held it in 21 quarters since.
  • Arax Advisory Partners's BioMarin Pharmaceuticals position peaked at $5.6M in Q3 2025.
  • 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.